title: Therapeutic use of cephazolin to prevent complications of spine surgery.
abstract: Discitis, caused by pyogenic organisms, is a potential complication of any procedure which involves entering the intervertebral disc during open or percutaneous procedures. While there are wide variations in the severity of symptoms, the characteristic feature of discitis is the development of increasingly severe back pain, which is not relieved by rest, or narcotic analgesics. While there is a tendency to spontaneous resolution over time, a self-limiting course does not always eventuate. Serious complications resulting from spread of the infective process can lead to vertebral osteomyelitis or to the formation of an epidural abscess with further risk of neural compression. Clinical and experimental evidence now supports the prophylactic use of a suitable antibiotic, but some uncertainties exist about the benefits of antibiotic therapy in treating established discitis. While cephazolin is a widely favoured choice of antibiotic, the timing of its administration to prevent or treat discitis has been complicated by the lack of suitable methods for detecting and measuring the concentration of cephazolin in the plasma and disc in experimental and clinical conditions. This paper describes a high-performance liquid chromatography technique for detecting the antibiotic cephazolin. The results conclude cephazolin can be detected in the plasma and disc after administering an intravenous bolus dose. However, concentration of cephazolin in the outer disc was 12 times greater than that of the inner disc.
authors.affiliation: The Adelaide Centre for Spinal Research, Institute of Medical and Veterinary Science, Frome Road, Adelaide, South Australia, 5000. Rebecca.walters@adelaide.edu.au
authors.forename: R
authors.initials: R
authors.lastname: Walters
authors.forename: B
authors.initials: B
authors.lastname: Vernon-Roberts
authors.forename: R
authors.initials: R
authors.lastname: Fraser
authors.forename: R
authors.initials: R
authors.lastname: Moore
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001682:Biological Availability; D002437:Cefazolin / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002851:Chromatography, High Pressure Liquid; D015299:Discitis / Q000209:etiology / Q000517:prevention & control*; D007275:Injections, Intravenous; D016015:Logistic Models; D019637:Orthopedic Procedures / Q000009:adverse effects*; D012756:Sheep; D013131:Spine / Q000378:metabolism* / Q000601:surgery
chemical_list: D000900:Anti-Bacterial Agents; D002437:Cefazolin